JADE BIOSCIENCES, INC.
NASDAQ: JBIO (Jade Biosciences, Inc.)
Last update: 2 hours ago21.51
-0.30 (-1.38%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Bullish |
| Biotechnology (Global) | Bullish | Bullish | |
| Stock | Jade Biosciences, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | -3.5 |
| Technical Oscillators | 2.0 |
| Average | -1.00 |
|
Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade’s pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.04% |
| % Held by Institutions | 33.40% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Fairmount Funds Management Llc | 31 Mar 2026 | 4,553,494 |
| Bellevue Group Ag | 31 Mar 2026 | 3,501,502 |
| Venrock Adviser, Llc | 31 Mar 2026 | 3,220,364 |
| Baker Bros. Advisors Lp | 31 Mar 2026 | 1,641,137 |
| Remedium Capital Partners, Llc | 31 Mar 2026 | 1,577,750 |
| Versant Venture Management, Llc | 31 Mar 2026 | 1,525,820 |
| Avidity Partners Management Lp | 31 Mar 2026 | 1,400,708 |
| Samsara Biocapital, Llc | 31 Mar 2026 | 968,798 |
| Great Point Partners I Lp | 31 Mar 2026 | 964,462 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |